These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37914618)

  • 1. Elevated Lipoprotein A Levels and Development of Moderate or Severe Cardiac Allograft Vasculopathy in Patients with Heart Transplants.
    González-Quijano M; Grande-Trillo A; Esteve-Ruiz I; Aranda-Dios A; Sobrino-Márquez JM; Rangel-Sousa D
    Transplant Proc; 2023 Dec; 55(10):2295-2298. PubMed ID: 37914618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epicardial fat volume is related to the degree of cardiac allograft vasculopathy.
    Roest S; Budde RPJ; Brugts JJ; von der Thüsen J; van Walsum T; Taverne YJHJ; Zijlstra F; Bos D; Manintveld OC
    Eur Radiol; 2023 Jan; 33(1):330-338. PubMed ID: 35986769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients.
    Raichlin E; McConnell JP; Bae JH; Kremers WK; Lerman A; Frantz RP
    Transplantation; 2008 Apr; 85(7):963-8. PubMed ID: 18408575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.
    Daly KP; Stack M; Eisenga MF; Keane JF; Zurakowski D; Blume ED; Briscoe DM
    J Heart Lung Transplant; 2017 Apr; 36(4):434-442. PubMed ID: 27865734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
    Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
    J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
    Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
    J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Analysis of Routine Biopsies Improves Diagnosis and Prediction of Cardiac Allograft Vasculopathy.
    Peyster EG; Janowczyk A; Swamidoss A; Kethireddy S; Feldman MD; Margulies KB
    Circulation; 2022 May; 145(21):1563-1577. PubMed ID: 35405081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention.
    Agarwal S; Parashar A; Kapadia SR; Tuzcu EM; Modi D; Starling RC; Oliveira GH
    JACC Heart Fail; 2014 Jun; 2(3):281-8. PubMed ID: 24952696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac allograft vasculopathy and survival in pediatric heart transplant recipients transitioned to adult care.
    Rodenas-Alesina E; Aleksova N; Stubbs M; Foroutan F; Kozuszko S; Posada JD; McDonald M; Moayedi Y; Ross H; Dipchand A
    J Heart Lung Transplant; 2024 Feb; 43(2):229-237. PubMed ID: 37704160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early aspirin use and the development of cardiac allograft vasculopathy.
    Kim M; Bergmark BA; Zelniker TA; Mehra MR; Stewart GC; Page DS; Woodcome EL; Smallwood JA; Gabardi S; Givertz MM
    J Heart Lung Transplant; 2017 Dec; 36(12):1344-1349. PubMed ID: 28781013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
    Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
    Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy: Systematic Findings and Risk Stratification by OCT.
    Clemmensen TS; Holm NR; Eiskjær H; Løgstrup BB; Christiansen EH; Dijkstra J; Barkholt TØ; Terkelsen CJ; Maeng M; Poulsen SH
    JACC Cardiovasc Imaging; 2017 Jul; 10(7):773-784. PubMed ID: 28330670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
    Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
    J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT).
    Zielińska K; Kukulski L; Wróbel M; Przybyłowski P; Rokicka D; Strojek K
    Ann Transplant; 2022 Feb; 27():e933420. PubMed ID: 35165250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers.
    Nandi D; Chin C; Schumacher KR; Fenton M; Singh RK; Lin KY; Conway J; Cantor RS; Koehl DA; Lamour JM; Kirklin JK; Pahl E
    J Heart Lung Transplant; 2020 Nov; 39(11):1260-1269. PubMed ID: 32861553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous coronary interventions and bypass surgery in patients with cardiac allograft vasculopathy: a single-center experience.
    Prada-Delgado O; Estévez-Loureiro R; López-Sainz A; Gargallo-Fernández P; Paniagua-Martín MJ; Marzoa-Rivas R; Barge-Caballero E; Cuenca-Castillo JJ; Castro-Beiras A; Crespo-Leiro MG
    Transplant Proc; 2012 Nov; 44(9):2657-9. PubMed ID: 23146485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study.
    Loupy A; Coutance G; Bonnet G; Van Keer J; Raynaud M; Aubert O; Bories MC; Racapé M; Yoo D; Duong Van Huyen JP; Bruneval P; Taupin JL; Lefaucheur C; Varnous S; Leprince P; Guillemain R; Empana JP; Levine R; Naesens M; Patel JK; Jouven X; Kobashigawa J
    Circulation; 2020 Jun; 141(24):1954-1967. PubMed ID: 32363949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.